Component

Human androgen receptor / AR

Human androgen receptor / AR. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Dihydrocapsaicin induced proliferation suppression in human prostate cancer cells by hindering the cell cycle at the G0/G1 phase, probably inhibited androgen receptor activity by blocking its movement from the cytoplasm to the nucleus through binding to the receptor ligand-binding domain, and mechanistically facilitated androgen receptor release from a stabilizing chaperone complex and enhanced its ubiquitination by E3 ligases resulting in partial degradation via the ubiquitin-proteasome pathway, while also reducing tumour growth in vivo.

    Dihydrocapsaicin → Human androgen receptor / AR source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/dihydrocapsaicin-research/41045970.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "232b30793c88e9e8fca6110ff6390d2d343ed78114d2daf849984cf2d2b80981", "start_char": 0, "end_char": 1566, "text_sha256": "232b30793c88e9e8fca6110ff6390d2d343ed78114d2daf849984cf2d2b80981"}
    experimental_model
    Human prostate cancer cell lines with in vivo tumour growth and in silico binding analysis
    exposure
    Dihydrocapsaicin applied to human prostate cancer cells and to xenografts
    limitations
    Combines cell, animal and computational arms. The binding to the ligand-binding domain is in silico and is recorded as such.
    nutrient_topic
    Dihydrocapsaicin research collection; topical membership is not evidence of a direct clinical effect, and dihydrocapsaicin is recorded separately from capsaicin. · Dihydrocapsaicin
    organism
    Human cells and mouse
    plain_language
    It stops the hormone receptor that drives prostate cancer from reaching the nucleus, and marks it for disposal.
    primary_references
    [dhc-p41045970] Androgen receptor inhibitory activity of dihydrocapsaicin: Insights from in vitro, in vivo and in silico studies. (2026). https://pubmed.ncbi.nlm.nih.gov/41045970/ DOI: 10.1016/j.jsbmb.2025.106872
    tissue_or_cell_type
    Prostate cancer

    Dihydrocapsaicin: the second capsaicinoid, the hypothermia it is used to induce, what the gut and liver do to it, and what it does without TRPV1 (2026-09-21) · lines 751–762

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Human prostate cancer cell lines with in vivo tumour growth and in silico binding analysis · source_derived_draft · unverified_draft

    ### dhc-androgen-receptor-inhibition Dihydrocapsaicin induced proliferation suppression in human prostate cancer cells by hindering the cell cycle at the G0/G1 phase, probably inhibited androgen receptor activity by blocking its movement from the cytoplasm to the nucleus through binding to the receptor ligand-binding domain, and mechanistically facilitated androgen receptor release from a stabilizing chaperone complex and enhanced its ubiquitination by E3 ligases resulting in partial degradation via the ubiquitin-proteasome pathway, while also reducing tumour growth in vivo. Condition category: normal nutrient_topic: Dihydrocapsaicin research collection; topical membership is not evidence of a direct clinical effect, and dihydrocapsaicin is recorded separately from capsaicin. plain_language: It stops the hormone receptor that drives prostate cancer from reaching the nucleus, and marks it for disposal. organism: Human cells and mouse tissue_or_cell_type: Prostate cancer experimental_model: Human prostate cancer cell lines with in vivo tumour growth and in silico binding analysis limitations: Combines cell, animal and computational arms. The binding to the ligand-binding domain is in silico and is recorded as such. exposure: Dihydrocapsaicin applied to human prostate cancer cells and to xenografts evidence_span: {"source_cache": "artifacts/dihydrocapsaicin-research/41045970.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "232b30793c88e9e8fca6110ff6390d2d343ed78114d2daf849984cf2d2b80981", "start_char": 0, "end_char": 1566, "text_sha256": "232b30793c88e9e8fca6110ff6390d2d343ed78114d2daf849984cf2d2b80981"} [dhc-p41045970] Androgen receptor inhibitory activity of dihydrocapsaicin: Insights from in vitro, in vivo and in silico studies. (2026). https://pubmed.ncbi.nlm.nih.gov/41045970/ DOI: 10.1016/j.jsbmb.2025.106872
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. After treatment, 96% of evaluable patients showed androgen-receptor nuclear exclusion, compared with none in pretreatment biopsies.

    3,3'-Diindolylmethane / DIM → Androgen receptor nuclear localization source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/dim-research/27069550.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7048d2f449ad8c31af0eb9e89b956d9d1dcebb0f74e1a4d0eabcc3635314053e", "start_char": 0, "end_char": 1626, "text_sha256": "7048d2f449ad8c31af0eb9e89b956d9d1dcebb0f74e1a4d0eabcc3635314053e"}
    experimental_model
    Pre-prostatectomy tissue and biomarker study
    exposure
    Absorption-enhanced DIM 225 mg twice daily for at least 14 days
    limitations
    Uncontrolled preoperative study. Tissue detection and altered localization do not establish tumor control, survival benefit or testosterone lowering.
    nutrient_topic
    Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. · 3,3'-Diindolylmethane / DIM
    organism
    28 evaluable men with localized prostate cancer
    plain_language
    A receptor changed location; this was not a randomized efficacy comparison.
    primary_references
    [dim-p27069550] Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. (2016). https://pubmed.ncbi.nlm.nih.gov/27069550/
    tissue_or_cell_type
    Prostate DIM, androgen-receptor localization and PSA

    Diindolylmethane (DIM): formation, receptor signaling, metabolism and drug interactions (2026-09-17) · lines 1143–1154

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Pre-prostatectomy tissue and biomarker study · source_derived_draft · unverified_draft

    ### dim-ar-exclusion After treatment, 96% of evaluable patients showed androgen-receptor nuclear exclusion, compared with none in pretreatment biopsies. Condition category: normal nutrient_topic: Diindolylmethane (DIM) research collection; topical membership is not evidence of a direct dietary effect. plain_language: A receptor changed location; this was not a randomized efficacy comparison. organism: 28 evaluable men with localized prostate cancer tissue_or_cell_type: Prostate DIM, androgen-receptor localization and PSA experimental_model: Pre-prostatectomy tissue and biomarker study limitations: Uncontrolled preoperative study. Tissue detection and altered localization do not establish tumor control, survival benefit or testosterone lowering. exposure: Absorption-enhanced DIM 225 mg twice daily for at least 14 days evidence_span: {"source_cache": "artifacts/dim-research/27069550.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7048d2f449ad8c31af0eb9e89b956d9d1dcebb0f74e1a4d0eabcc3635314053e", "start_char": 0, "end_char": 1626, "text_sha256": "7048d2f449ad8c31af0eb9e89b956d9d1dcebb0f74e1a4d0eabcc3635314053e"} [dim-p27069550] Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients. (2016). https://pubmed.ncbi.nlm.nih.gov/27069550/
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards